This study uses US tuberculosis (TB) surveillance data to describe demographic, risk factor, and treatment outcome information for persons with isoniazid-monoresistant TB compared with persons with TB susceptible to all first-line anti-TB drugs. The number of isoniazid-monoresistant TB cases increased from 303 (4.1%) in 1993 to 351 (4.3%) in 2005. In our multivariate analysis of all TB cases reported from 1993 to 2003, patients with isoniazid-monoresistant TB were significantly more likely to be US-born Asian (adjusted odds ratio [aOR], 1.9; confidence interval [CI], 1.4-2.6), US-born Hispanic (aOR, 1.3; 95% CI, 1.1-1.5), foreign-born Asian (aOR, 1.8; 95% CI, 1.4-2.1), or foreign-born black (aOR, 1.4; 95% CI, 1.1-1.7). Isoniazid monoresistance was also associated with history of TB (aOR, 1.5; 95% CI, 1.3-1.7), failure to complete therapy within 1 year (aOR, 1.7; 95% CI, 1.5-1.8), and correctional facility residence (aOR, 1.5; 95% CI, 1.2-1.7).